Navigation Links
Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Date:10/23/2008

d CloniBID to treat hypertension. Clonicel is currently in phase 3 trials, and a new drug application has been filed for CloniBID with FDA review expected by the end of the year. Commercial rights to both drugs, and to ADX415, have been granted to Atlanta-based Sciele Pharma, a Shionogi Company.

About Addrenex Pharmaceuticals, Inc.

Addrenex Pharmaceuticals is a focused specialty pharmaceutical company that develops and commercializes drugs to treat adrenergic dysregulation. Addrenex Pharmaceuticals is based in Durham, N.C., on the edge of Research Triangle Park. The company was formed in 2006 by a practicing physician and a drug development expert with the mission to explore the impact that neurotransmitter regulation has on a variety of diseases and disorders. Addrenex identified adrenergic regulation as its initial research focus. Adrenergic dysregulation is implicated in medical conditions such as hypertension, ADHD, migraines and postmenopausal symptoms. Addrenex will use the knowledge and experience gained from developing CloniBID and Clonicel as the foundation for additional discovery and development in the area of adrenergic regulation.


'/>"/>
SOURCE Addrenex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
2. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... VEGAS , Jan. 23, 2015 Cord Blood America, ... ) ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, ... www.sec.gov ) today, and provides an update for shareholders detailing ... shares is requested. Dear Shareholders, As ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
(Date:1/22/2015)... 2015  BiOptix is pleased to announce the appointment of ... Chemistry and Biochemistry. Scott joins the company after previous scientific ... throughout the course of his nearly 20 year career ... a nationally recognized thought leader in the biosensor field ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Dey Pharma, L.P. today announced that it has ... specialty pharma company headquartered in Sweden, for the exclusive ... Europe. EpiPen Auto-Injector is used for emergency treatment of ... within a couple of minutes, and may be life-threatening. ...
... BURLINGTON, Mass., Dec. 23, 2010 Decision Resources, one of ... healthcare issues, finds that 60 percent of surveyed type 2 ... they would request that their doctor switch them to a ... The new Patient Forum report entitled ...
Cached Medicine Technology:Mylan's Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe 2Mylan's Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe 3Sixty Percent of Surveyed Type 2 Diabetes Patients in the U.S. Who Use Insulin Indicate They Would Request a Switch to a Less Expensive Biosimilar Insulin if Such an Agent Became Available 2
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... 22, 2015 As interest in the value ... gains momentum worldwide, Rev. Eric J. Hall , president ... (HCCN), will be the keynote speaker on January 27 ... public health system. , The conference, “Hope and Resilience: Innovative ...
(Date:1/22/2015)... January 22, 2015 Compare-autoinsurance.org has released a new ... by an auto insurance policy . , Some types ... Clients should check the newly released blog post to see if ... and dangerously damaged vehicles are some of the cars that cannot ...
(Date:1/22/2015)... Step into a macabre world where ... of Virginia. Wicked Plants, the Museum’s latest featured exhibition, ... poisonous, carnivorous and diabolical plants inside of a dilapidated, ... the biochemical, physical and neurological processes between botanicals and ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... , WASHINGTON, July 28 Tonight, ... Family Research Council Action President Tony Perkins unveiled a new ... Pennsylvania, Arkansas, Alaska, Louisiana, and Nebraska. The hard hitting ad lays ... rationing and taxpayer funded abortions. Patients, particularly the elderly, ...
... , DETROIT, July 28 Caraco Pharmaceutical Laboratories, ... N. Doshi has been appointed as interim Chief Executive Officer ... of Daniel H. Movens as Chief Executive Officer and as ... Mr. Movens, tenure, Caraco experienced substantial product expansion and revenue ...
... use begins before age 30, international panel says , TUESDAY, ... on Cancer on Tuesday moved tanning beds to its highest ... new report. , Previously, the agency had classified sunlamps and ... devices a notch higher in terms of risk. It also ...
... , WASHINGTON, July 28 The American Dental Association (ADA) ... to place any restriction on the use of dental amalgam, a commonly ... Multimedia News Release, go to: http://www.prnewswire.com/mnr/ada/39331/ ... dental amalgam as a class II medical device, placing it in the ...
... , , , ... in Maine could lose their private, employer-based coverage if Congress passes a ... American Affordable Health Choices Act of 2009 released this week ... Heritage commissioned The Lewin Group , a ...
... , CINCINNATI, July 28 ... Meeting of the American Society for Metabolic & Bariatric Surgery ... mounting data about how the biochemical and endocrine effects of ... for patients battling the co-morbid conditions associated with obesity, particularly ...
Cached Medicine News:Health News:FRC Action Launches TV Ad Campaign On Government Health Care Takeover 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Position of CEO 2Health News:Tanning Beds Get Highest Carcinogen Rating 2Health News:Tanning Beds Get Highest Carcinogen Rating 3Health News:Video: American Dental Association Statement: Food and Drug Administration Action on Dental Amalgam 2Health News:Thousands of Maine Residents Could Lose Private Insurance, Study Shows 2Health News:Ethicon Endo-Surgery Holds Metabolic Surgery Scientific Forum Featuring Research By Top Scientists 2Health News:Ethicon Endo-Surgery Holds Metabolic Surgery Scientific Forum Featuring Research By Top Scientists 3Health News:Ethicon Endo-Surgery Holds Metabolic Surgery Scientific Forum Featuring Research By Top Scientists 4
... Used for cystometry and urethral ... allows for faster filling of the ... readings. Dual lumen catheter construction allows ... cystometry is performed. Triple lumen catheter ...
... SAFE-T-FILL Capillary Blood Collection Tubes are 100% ... a wide range of applications, the Capillary ... tube, attached cap and a micro tube.,The ... the blood into the micro tube thereby ...
... Scientifics SAFE-T-FILL Capillary Blood Collection Tubes are ... for a wide range of applications, the ... capillary tube, attached cap and a micro ... draw the blood into the micro tube ...
... RAM Scientifics SAFE-T-FILL Capillary Blood Collection ... systems. Available for a wide range of ... with a capillary tube, attached cap and ... action to draw the blood into the ...
Medicine Products: